Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- LDP Inscribes AI Utilization for Drug Development in Honebuto Paper
June 19, 2019
- PMDA to Strengthen Grad/Mid-Career Hiring Strategy, Increase Operating Efficiency with AI
June 19, 2019
- 2 PMDA Advisors Infringe COI Rules; No Impact on Product Approvals
June 18, 2019
- PMDA to Prohibit Staffers from Trading Pharma Shares
June 17, 2019
- PMDA to Discuss Optimal Use of Xofluza amid Concerns over Resistant Viruses
June 17, 2019
- 10 More Hospitals to Join MID-NET Database, Covering Data on 6 Million Patients
June 17, 2019
- PMDA Reviewing Risks for Ibrance, Opdivo, Keytruda and More
June 17, 2019
- LDP’s Pharma Study Group Submits Proposal to Health Minister, Calls for PMP Revamp in 2020 Reform
June 13, 2019
- Nesp Biosame to Join NHI Price List, Launch Due by September; Symbicort Generics, Teribone AG Skip Listing
June 13, 2019
- Govt’s Draft Policy Blueprint Prods Continued Debates on Pricing Reform Proposals; Expanded HTA Use, Handling of PMP-Granted Comparators and More
June 12, 2019
- PMDA Chief Mulls Requiring Few-Year Clinical Background for Reviewers
June 12, 2019
- PMDA to Form Panel on Relief System to Ensure Access, Quick Remedy
June 11, 2019
- MHLW Study Group Drafting Guidelines for New Dyslipidemia Drug Development, First in 30 Years
June 11, 2019
- Deregulation Panel Proposes Giving Private Companies Access to National Health Database to Promote New Drug Development
June 10, 2019
- MHLW Vaccine Panel Discusses Inclusion of Rotavirus Vaccine in Public Vaccination Programs; Has “Enough Data”
June 7, 2019
- Shock, Anaphylaxis Added to Xofluza’s ADR List; Label Changes for Checkpoint Blockers
June 5, 2019
- MHLW Panel Approves to Contraindicate Metformin in Impaired Kidney Function Patients with eGFR less than 30
June 4, 2019
- Reborn PMDA Boots Up under New Skipper, Bolstering “Patient First” Initiatives
June 4, 2019
- Kampo Industry Expresses Concerns over Copay Hikes, Narrow Definition of Essential Drugs: LDP League
June 3, 2019
- Bayer’s Larotrectinib, Novartis’ Capmatinib Get Orphan Status in Japan
June 3, 2019
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…